{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:03:28Z","timestamp":1748837008387,"version":"3.41.0"},"reference-count":27,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5582\/ddt.2015.01066","type":"journal-article","created":{"date-parts":[[2016,1,17]],"date-time":"2016-01-17T22:04:50Z","timestamp":1453068290000},"page":"404-410","source":"Crossref","is-referenced-by-count":4,"title":["High prevalence of &lt;i&gt;VKORC1*3&lt;\/i&gt; (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol"],"prefix":"10.5582","volume":"9","author":[{"given":"Tushar","family":"Sehgal","sequence":"first","affiliation":[{"name":"Department of Hematology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasbir Kaur","family":"Hira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Hematology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Vijayvergiya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip Singh","family":"Rana","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Postgraduate Institute of Medical Education and Research"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992; 45:704-706.","DOI":"10.1136\/jcp.45.8.704"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Leung AY, Chow HC, Kwong YL, Fung AT, Chow WH, Yip AS, Liang R. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98:2584-2587.","DOI":"10.1182\/blood.V98.8.2584"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106:135-140.","DOI":"10.1182\/blood-2005-01-0341"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wolf CR, Smith G. Pharmacogenetics. Br Med Bull. 1999; 55:366-386.","DOI":"10.1258\/0007142991902439"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000; 28:1284-1290.","DOI":"10.1016\/S0090-9556(24)15074-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352:2285-2293.","DOI":"10.1056\/NEJMoa044503"},{"key":"7","unstructured":"7. Kaur A, Khan F, Agrawal SS, Kapoor A, Agarwal SK, Phadke SR. Cytochrome P450 (<i>CYP2C9*2,*3<\/i>) &amp; vitamin-K epoxide reductase complex (<i>VKORC1-1639G&lt;A<\/i>) gene polymorphisms &amp; their effect on acenocoumarol dose in patients with mechanical heart valve replacement. Indian J Med Res. 2013; 137:203-209."},{"key":"8","unstructured":"8. Rathore S, Agarwal S, Pande S, Mittal T, Mittal B. Frequencies of <i>VKORC1<\/i> -1639 G&gt;A, <i>CYP2C9*2<\/i> and <i>CYP2C9*3<\/i> genetic variants in the Northern Indian population. BioSci Trends. 2010; 4:333-337."},{"key":"9","unstructured":"9. Madhan S, Kumar D, Kumar D, Balachander J, Adithan C. Effect of <i>CYP2C9<\/i> and <i>VKORC1<\/i> genetic polymorphisms on warfarin dose requirement in south Indian population. Indian J Physiol Pharmacol. 2013; 57:308-317."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nahar R, Deb R, Saxena R, Puri R, Verma I. Variability in <i>CYP2C9<\/i> allele frequency: A pilot study of its predicted impact on warfarin response among healthy South and North Indians. Pharmacol Rep. 2013; 65:187-194.","DOI":"10.1016\/S1734-1140(13)70977-0"},{"key":"11","unstructured":"11. Shalia K, Doshi S, Parikh S, Pawar P, Divekar S, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D. Prevalence of <i>VKORC1<\/i> and <i>CYP2C9<\/i> gene polymorphisms in Indian population and its effect on Warfarin response. JAPI."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(suppl):8S-21S.","DOI":"10.1378\/chest.119.1_suppl.8S"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the <i>CYP2C9<\/i>-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6:341-349.","DOI":"10.1097\/00008571-199608000-00007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sipeky C, Csongei V, Jaromi L, Safrany E, Polgar N, Lakner L, Szabo M, Takacs I, Melegh B. Vitamin K epoxide reductase complex 1 (<i>VKORC1<\/i>) haplotypes in healthy Hungarian and Roma population samples. Pharmacogenomics. 2009; 10:1025-1032.","DOI":"10.2217\/pgs.09.46"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borobia A, Lubomirov R, Ramirez E, Lorenzo A, Campos A, Munroz-Romo R, Fern\u00e1ndez-Capit\u00e1n C, Fr\u00edas J, Carcas AJ. Acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One. 2012; 7:1-10.","DOI":"10.1371\/journal.pone.0041360"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of <i>CYP2C9<\/i> and <i>VKORC1<\/i> genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood. 2005; 106:2329-2333.","DOI":"10.1182\/blood-2005-03-1108"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Arboix M, Laporte J, Frati M, Rutllan M. Effect of age and sex on acenocoumarol requirements. Br J Clin Pharmac. 1984; 18:475-479.","DOI":"10.1111\/j.1365-2125.1984.tb02494.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland van der Zee AH. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics. 2009; 10:1687-1695.","DOI":"10.2217\/pgs.09.125"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: Dose-response relationships in healthy subjects. Blood. 2004; 104:2682-2689.","DOI":"10.1182\/blood-2004-04-1525"},{"key":"20","unstructured":"21. Takahashi H, Wilkinson G, Padrini R, Echizen H. <i>CYP2C9<\/i> and oral anticoagulation therapy with acenocoumarol and warfarin: Similarities yet differences."},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Krishna Kumar D, Madhan S, Balachander J, Sai Chandran BV, Thamijarassy B, Adithan C. Effect of <i>CYP2C9<\/i> and <i>VKORC1<\/i> genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res. 2013; 131:363-367.","DOI":"10.1016\/j.thromres.2013.02.006"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Scott S, Khasawneh R, Kornreich I, Desnick R. Combined <i>CYP2C9<\/i>, <i>VKORC1<\/i> and <i>CYP4F2<\/i> frequencies among racial and ethnic groups. Pharmacogenomics. 2010; 11:781-791.","DOI":"10.2217\/pgs.10.49"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, Ng KS, Soong R, Goh BC. Interethnic variability of warfarin maintenance requirement is explained by <i>VKORC1<\/i> genotype in an Asian population. Clin Pharmacol Ther. 2006; 79:197-205.","DOI":"10.1016\/j.clpt.2005.11.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Hermida J, Zarza J, Alberca I, Montes R, L\u00f3pez M, Molina E. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 <i>CYP2C9<\/i> on sensitivity to acenocoumarol. Blood. 2002; 99:4237-4239.","DOI":"10.1182\/blood.V99.11.4237"},{"key":"25","unstructured":"26. Gan G, Lee M, Subramaniam R, Lu L, Tai M, Phipps M. Allele and Genotype frequencies of <i>VKORC1<\/i> -1639G&gt;A polymorphism in three different ethnic groups in Malaysia. As Pac J Mol Biol Biotechnol. 2012; 20:19- 23."},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding <i>VKORC1<\/i> Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007; 109:2477-2480.","DOI":"10.1182\/blood-2006-08-038984"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, M\u00fcller CR, Wienker TF, Oldenburg J. <i>VKORC1<\/i> haplotypes and their impact on the inter-individual and interethnical variability of oral anticoagulation. Thromb Haemost. 2005; 94:773-779.","DOI":"10.1160\/TH05-04-0290"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/9\/6\/9_2015.01066\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:40:00Z","timestamp":1748752800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/9\/6\/9_2015.01066\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2015.01066","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"type":"print","value":"1881-7831"},{"type":"electronic","value":"1881-784X"}],"subject":[],"published":{"date-parts":[[2015]]}}}